![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
As the length of product cycles gets more compressed, the economic lifetime of a viable technology is getting shorter. Valuing an investment inherently involves within the calculation the factor of time. This is true within biotech and computer software, hardware, etc. Occasionally (occasionally), proponents of a given company overstate the economic lifetime of an apparantly good development. Other times, the lifetime may be underappreciated. Short sale candidates are often technology stocks who miss product cycle shifts and get stuck with unsold inventory. Or, a biotech firm that just spent $100 million on a promising drug believing that THEY would have the best product for disease "X" for 10 years. Analysts model a growth curve extending out 9 years for conservatism. WHOOPS! Forgot that the market was so big that 73 firms worldwide were working on the same problem? Hopefully, this can be a thread to discuss technologies with less bull and bear bashing of individual companies.
| ||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |